AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22283027 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant lactoferrin for 8 weeks
Number of subjects: 30
Study 22283027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19419331 — intervention group
Group type: COMPARATOR
Intervention: Standard caspofungin regimen (50 mg/day after a 70 mg dose on day 1)
Number of subjects: 204
Study 19419331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caspofungin regimen (150 mg/day)
Number of subjects: 204
Study 19419331 — intervention group
Group type: COMPARATOR
Intervention: Standard caspofungin regimen
Number of subjects: 204
Study 19419331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caspofungin regimen
Number of subjects: 204
Study 19419331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 204
Study 16782716 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 62
Study 16782716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) combined with substrate modification (SM)
Number of subjects: 62
Study 15496641 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly)
Number of subjects: 682
Study 15496641 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly) plus Methotrexate (weekly oral dose, median 20 mg)
Number of subjects: 682
Study 15496641 — intervention group
Group type: COMPARATOR
Intervention: Control group (Methotrexate alone not specified)
Number of subjects: 682
Study 11778664 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,3-dimercapto-1-propanesulfonate 100-mg capsules 4 times a day for 1 week, repeated in the 3rd, 5th, and 7th week
Number of subjects: 21
Study 11778664 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules resembling 2,3-dimercapto-1-propanesulfonate
Number of subjects: 21
Study 9102259 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 39
Study 9102259 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for colon carcinoma
Number of subjects: 39
Study 9102259 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for rectal carcinoma
Number of subjects: 39
Study 8385284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard 20 mg
Number of subjects: 10
Study 8385284 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 10
Study 3511766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia (freezing of the ilioinguinal nerve)
Number of subjects: 36
Study 3511766 — intervention group
Group type: COMPARATOR
Intervention: No cryoanalgesia (control group)
Number of subjects: 36
Study 29345113 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents-only intervention group (n=89)
Number of subjects: 247
Study 29345113 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents-and-child intervention group (n=84)
Number of subjects: 247
Study 29345113 — intervention group
Group type: COMPARATOR
Intervention: Follow-up alone control group (n=74)
Number of subjects: 247
Study 29345113 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 247
Study 27571269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention formula with equal amounts of AA and DHA (IF)
Number of subjects: 0
Study 27571269 — intervention group
Group type: COMPARATOR
Intervention: Control formula without additional AA and DHA (CF)
Number of subjects: 0
Study 27571269 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (BM)
Number of subjects: 0
Study 23813124 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring sleep diary and response inhibition training
Number of subjects: 190
Study 23813124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep diary only
Number of subjects: 190
Study 23813124 — intervention group
Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 190
Study 22278627 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dialysis for 1 week after standard hemodialysis (HD) for 1 week
Number of subjects: 60
Study 22278627 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (HD) for 1 week after daily dialysis for 1 week
Number of subjects: 60
Study 20507582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined screening program for AAA, PAD, and hypertension
Number of subjects: 50000
Study 18778208 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphony breast pump (SBP)
Number of subjects: 100
Study 18778208 — intervention group
Group type: COMPARATOR
Intervention: Classic breast pump (CBP)
Number of subjects: 100
Study 18778208 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-phase suction pattern in SBP
Number of subjects: 100
Study 18778208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphase suction pattern in SBP
Number of subjects: 100
Study 15667660 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg)
Number of subjects: 14
Study 15667660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15667660 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (10 and 100 microg/ml) - ex-vivo treatment
Number of subjects: 14
Study 12195131 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 628
Study 12195131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 10429624 — intervention group
Group type: EXPERIMENTAL
Intervention: SSG II protocol
Number of subjects: 223
Study 10429624 — intervention group
Group type: EXPERIMENTAL
Intervention: SSG VIII protocol
Number of subjects: 223
Study 10429624 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 223
Study 7594338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 30 mg q.d. for 8 weeks in GU and 6 weeks in DU
Number of subjects: 0
Study 7594338 — intervention group
Group type: COMPARATOR
Intervention: Roxatidine (R) 75 mg b.i.d. for 8 weeks in GU and 6 weeks in DU
Number of subjects: 0
Study 7594338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ)
Number of subjects: 0
Study 7594338 — intervention group
Group type: COMPARATOR
Intervention: Roxatidine (R)
Number of subjects: 0
Study 2135068 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml 20%)
Number of subjects: 0
Study 2135068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 0
Study 6107452 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol, 40 mg three times a day
Number of subjects: 473
Study 6107452 — intervention group
Group type: COMPARATOR
Intervention: disopyramide phosphate, 150 mg three times a day
Number of subjects: 473
Study 6306388 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 50 mg/day
Number of subjects: 18
Study 6306388 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-421 10 mg/day
Number of subjects: 18
Study 6306388 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 50 mg/day plus MK-421 10 mg/day
Number of subjects: 18
Study 31185057 — intervention group
Group type: EXPERIMENTAL
Intervention: Park Prescription intervention including face-to-face counseling and weekly structured exercise sessions in the park.
Number of subjects: 97
Study 31185057 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise sessions on weekday evenings or weekend mornings.
Number of subjects: 97
Study 31185057 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to increase physical activity in parks.
Number of subjects: 97
Study 29279010 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 81
Study 29279010 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 81
Study 29279010 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorganisation symptoms
Number of subjects: 81
Study 27711083 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT plus vandetanib (100 mg once daily for 3 weeks)
Number of subjects: 24
Study 27711083 — intervention group
Group type: COMPARATOR
Intervention: Placebo with WBRT (30 Gy in 10 fractions)
Number of subjects: 24
Study 24702135 — intervention group
Group type: EXPERIMENTAL
Intervention: CTR+HR
Number of subjects: 12
Study 24702135 — intervention group
Group type: COMPARATOR
Intervention: CTR
Number of subjects: 12
Study 22226086 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg QD
Number of subjects: 29
Study 22226086 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg BID
Number of subjects: 29
Study 22226086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 20409057 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (conducted by two nurses)
Number of subjects: 46
Study 20409057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 17652648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg per kilogram of body weight)
Number of subjects: 600
Study 17652648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 16232039 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions focused on the Internet's information tools
Number of subjects: 117
Study 16232039 — intervention group
Group type: COMPARATOR
Intervention: Instructions focused on the Internet's communication tools
Number of subjects: 117
Study 16232039 — intervention group
Group type: COMPARATOR
Intervention: Basic instructions about how to use the Internet
Number of subjects: 117
Study 12387530 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-made oral supplement (group A)
Number of subjects: 66
Study 12387530 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-made oral supplement (group B)
Number of subjects: 66
Study 12387530 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 66
Study 10460068 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial intravenous dose of 50 mg ranitidine; followed by either repeated injections (50 mg every 6 hours) or a continuous infusion (50 mg plus 0.125 mg/kg/h)
Number of subjects: 18
Study 10460068 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 8528053 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms/m2
Number of subjects: 61
Study 8528053 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms/m2
Number of subjects: 61
Study 8528053 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms/m2
Number of subjects: 61
Study 8528053 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose groups
Number of subjects: 61
Study 8528053 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose groups
Number of subjects: 61
Study 2192011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (1.5 x 10(6) IU) injected intralesionally plus podophyllin resin applied topically once weekly for 3 weeks
Number of subjects: 97
Study 2192011 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin alone
Number of subjects: 97
Study 2192011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b plus podophyllin
Number of subjects: 97
Study 380730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 14
Study 380730 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 14
Study 31560067 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrelia burgdorferi seropositivity (Bb+)
Number of subjects: 689
Study 31560067 — intervention group
Group type: COMPARATOR
Intervention: Borrelia burgdorferi seronegativity (Bb-)
Number of subjects: 689
Study 31856760 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.05 μg·kg−1·h−1)
Number of subjects: 69
Study 28893201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 8 cm H2O
Number of subjects: 90
Study 28893201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 10 cm H2O
Number of subjects: 90
Study 28893201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 12 cm H2O
Number of subjects: 90
Study 28893201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 14 cm H2O
Number of subjects: 90
Study 28893201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 16 cm H2O
Number of subjects: 90
Study 28327481 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised exercises
Number of subjects: 140
Study 28327481 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 140
Study 25099866 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-lotrafilcon A
Number of subjects: 140
Study 25099866 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-lotrafilcon B
Number of subjects: 140
Study 25099866 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfilcon A
Number of subjects: 140
Study 25099866 — intervention group
Group type: EXPERIMENTAL
Intervention: Galyfilcon A
Number of subjects: 140
Study 25099866 — intervention group
Group type: COMPARATOR
Intervention: Other SiHy lenses (balafilcon A, comfilcon A, enhanced-lotrafilcon A, enhanced-lotrafilcon B, enfilcon A, galyfilcon A)
Number of subjects: 140
Study 21593283 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of celiprolol (100 mg)
Number of subjects: 30
Study 21593283 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose of celiprolol (97.5 µg)
Number of subjects: 30
Study 18073779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g per day PS-enriched spread
Number of subjects: 0
Study 18073779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17581778 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment withdrawn
Number of subjects: 3029
Study 17581778 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker dose reduction
Number of subjects: 3029
Study 17581778 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker maintained on the same dose
Number of subjects: 3029
Study 15037890 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol maleate fixed combination (LTFC) given once daily
Number of subjects: 32
Study 15037890 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine twice daily and latanoprost once daily
Number of subjects: 32
Study 15037890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LTFC and brimonidine/latanoprost
Number of subjects: 32
Study 11418458 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP with interferon
Number of subjects: 504
Study 11418458 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP with high-dose cyclophosphamide
Number of subjects: 504
Study 11418458 — intervention group
Group type: COMPARATOR
Intervention: VBMCP alone
Number of subjects: 504
Study 11418458 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (VBMCP with interferon, high-dose cyclophosphamide, or VBMCP alone)
Number of subjects: 504
Study 9249104 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication (0.04 mg/kg)
Number of subjects: 30
Study 9249104 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 30
Study 8282425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrices (0.3% Triclosan with 0.75% zinc citrate)
Number of subjects: 0
Study 8282425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/Gantrez dentifrice (2% Gantrez)
Number of subjects: 0
Study 8282425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/zinc citrate group
Number of subjects: 0
Study 8282425 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 3541714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of caffeine in solution orally
Number of subjects: 8
Study 3541714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30986140 — intervention group
Group type: EXPERIMENTAL
Intervention: Older hearing-impaired listeners (OHI)
Number of subjects: 49
Study 30986140 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-matched normal-hearing listeners
Number of subjects: 49
Study 30986140 — intervention group
Group type: EXPERIMENTAL
Intervention: Young normal-hearing listeners (YNH)
Number of subjects: 49
Study 30986140 — intervention group
Group type: COMPARATOR
Intervention: Overall performance
Number of subjects: 49
Study 26756554 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 intra-detrusor injections of Dysport 750 U
Number of subjects: 47
Study 26756554 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 intra-detrusor injections of Dysport 750 U
Number of subjects: 47
Study 26756554 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 injections
Number of subjects: 47
Study 26756554 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 injections
Number of subjects: 47
Study 26756554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport groups (both 15 and 30 injections)
Number of subjects: 47
Study 26756554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport groups
Number of subjects: 47
Study 25678687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment
Number of subjects: 28
Study 25678687 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 23771427 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy metal music
Number of subjects: 21
Study 23771427 — intervention group
Group type: COMPARATOR
Intervention: Baroque music
Number of subjects: 21
Study 20970129 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen needle retrieval (direct follicular aspiration)
Number of subjects: 0
Study 20970129 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen needle retrieval (follicular flushing)
Number of subjects: 0
Study 19735512 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration HA fillers (24 mg/mL) - Juvéderm Ultra, Ultra Plus, and 30
Number of subjects: 160
Study 19735512 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration HA fillers (5.5 mg/mL) - Hylaform, Hylaform Plus, and Captique
Number of subjects: 160
Study 17001566 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 105
Study 17001566 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 105
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Related Quality of Life (HRQoL) measured using EuroQoL-5D questionnaire
Number of subjects: 268
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical problems related to care
Number of subjects: 268
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological problems
Number of subjects: 268
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Burden perceived measured using Zarit scale
Number of subjects: 268
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Time commitment (hours per day)
Number of subjects: 268
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-sanitary help received
Number of subjects: 268
Study 15388064 — intervention group
Group type: EXPERIMENTAL
Intervention: Help from Alzheimer's Patient Family Associations (APFA)
Number of subjects: 268
Study 11453908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol 2% cream + Clobetasol-17-propionate 0.05% ointment
Number of subjects: 8
Study 11453908 — intervention group
Group type: COMPARATOR
Intervention: Dithranol 2% cream + Vehicle
Number of subjects: 8
Study 8782257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 24
Study 8782257 — intervention group
Group type: COMPARATOR
Intervention: No cyclosporine (control group)
Number of subjects: 24
Study 1417691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral treatments
Number of subjects: 90
Study 1417691 — intervention group
Group type: COMPARATOR
Intervention: Psychological tests (MMPI, BDI, STAI) and demographic variables
Number of subjects: 90
Study 6373441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 18
Study 6373441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg
Number of subjects: 18
Study 6373441 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 18
Study 31177856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (subcutaneous injection, IgG2Δa)
Number of subjects: 0
Study 31177856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 0
Study 29976211 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based testing
Number of subjects: 93
Study 29976211 — intervention group
Group type: COMPARATOR
Intervention: Text-based testing
Number of subjects: 93
Study 29976211 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based training
Number of subjects: 93
Study 27348908 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints on the axillary nerve distribution (Jianjing, Jianzhen, Jianliao, Jianyu, Quyuan, Tianzong, and trigger points in the scapular region) with Hegu needling and electric stimulation (continuous wave, 1Hz) for 30 min, once every two days for 10 treatments.
Number of subjects: 80
Study 27348908 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture at Dazhui, Tianzhu, Houxi, and cervical Jiaji (EX-B 2) with electric stimulation at cervical Jiaji (EX-B 2) for 30 min, once every two days for 10 treatments.
Number of subjects: 80
Study 25019969 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose sodium picosulfate plus magnesium citrate (PMC)
Number of subjects: 862
Study 25019969 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose sodium picosulfate plus magnesium citrate (PMC)
Number of subjects: 862
Study 25019969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 862
Study 21840967 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus counselling
Number of subjects: 0
Study 21840967 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus counselling
Number of subjects: 0
Study 20850778 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote perconditioning (n = 28)
Number of subjects: 81
Study 20850778 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote preconditioning (n = 26)
Number of subjects: 81